Muscleblind-like 1 (MBNL1) is a ubiquitously expressed
RNA-binding protein, which is highly expressed in skeletal muscle. Abnormally expanded CUG-repeats in the DMPK gene cause
myotonic dystrophy type 1 (DM1) by sequestration of MBNL1 to
nuclear RNA foci and by upregulation of another
RNA-binding protein, CUG-
binding protein 1 (CUGBP1). We previously reported that a nonsteroidal anti-inflammatory drug (
NSAID),
phenylbutazone, upregulates MBNL1 expression in DM1 mouse model by demethylation of MeR2, an enhancer element in Mbnl1 intron 1.
NSAIDs inhibit
cyclooxygenase (COX), which is comprised of COX-1 and COX-2
isoforms. In this study, we screened 29
NSAIDs in C2C12 myoblasts, and found that 13
NSAIDs enhanced Mbnl1 expression, where COX-1-selective
NSAIDs upregulated Mbnl1 more than COX-2-selective
NSAIDs. Consistently, knockdown of COX-1, but not of COX-2, upregulated MBNL1 expression in C2C12 myoblasts and myotubes, as well as in myotubes differentiated from DM1 patient-derived induced pluripotent stem cells (iPSCs).
Luciferase assay showed that COX-1-knockdown augmented the MeR2 enhancer activity. Furthermore,
bisulfite sequencing analysis demonstrated that COX-1-knockdown suppressed methylation of MeR2. These results suggest that COX-1 inhibition upregulates Mbnl1 transcription through demethylation of the MeR2 enhancer. Taken together, our study provides new insights into the transcriptional regulation of Mbnl1 by the COX-1-mediated pathway.